drugset / Trial / NCT02033148

Icotinib Hydrochloride in Treating Patients With Advanced Cancers

NCT02033148

Phase 1 Withdrawn Roswell Park Cancer Institute
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial studies the side effects and best dose of icotinib hydrochloride in treating patients with advanced cancers. Icotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2014-08
Primary completion
2016-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Icotinib Small molecule Oral